| ²é¿´: 1257 | »Ø¸´: 2 | |||
dylfgsľ³æ (ÖøÃûдÊÖ)
ÖÐÀɽ«
|
[½»Á÷]
0.01% w/v of simvastatin BPCRS in solution A.
|
|
ÇëÎÊ£º2013°æBPÖжÔÐÁ·¥Ëû͡ƬµÄÒªÇóÖУ¬ÓйØÎïÖʵIJⶨÖУ¬ÓÐÈçÏ¡°Mobile phase A 50 volumes of acetonitrile and 50 volumes of a 0.1% v/v solution of orthophosphoric acid . (2) 0.01% w/v of simvastatin BPCRS in solution A. (3) 0.002% w/v of each of simvastatin BPCRS and lovastatin EPCRS. (4) 0.1% w/v of simvastatin for peak identification EPCRS. ¡±£¨2(3)(4)ÖеÄÃèÊöÊÇÉñÃÅÒâ˼£¬Êǽ«simvastatin BPCRS ÈÜÓÚsolution AÖУ¬ÅäÖÆ³É0.01%µÄÈÜÒºÂ𣿠½«simvastatin BPCRS and lovastatin EPCRS.ÅäÖÆ³É0.002%µÄÈÜÒº£¬ ½« simvastatin for peak identification EPCRSÅäÖÆ³É0.1%µÄÈÜÒºÂ𣿠Çë´ó¼Ò·¢±í×Ô¼ºµÄ¼û½â£¬Ð»Ð»£¬¸Ð¼¤ÌéÁã |
» ²ÂÄãϲ»¶
ÉúÎï×éÖ¯ÖÐÓÐÄ¿±ê·ÖÎöÎרÊôÐÔÔõô×ö
ÒѾÓÐ0È˻ظ´
2026Éê²©ÍÆ¼ö
ÒѾÓÐ1È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ280È˻ظ´
һƪÀ©É¢Ä£Ð͵ÄNature Machine IntelligenceÂÛÎĺÍElsevierÉϵÄÉî¶ÈѧϰҩÎïÊé¼®
ÒѾÓÐ1È˻ظ´
ÖйúÒ©¿Æ´óѧ2026Èëѧ²©Ê¿£¬Ò©ÎïºÏ³ÉºÍÉè¼Æ¾Ñ飬·ÅÉ仯ѧ¼°·ÅÉäҽѧÑо¿
ÒѾÓÐ25È˻ظ´
ʹÓÃMolAICal½øÐжàëÄÐéÄâɸѡ½Ì³Ì-ͬÑùÊÊÓÃÓÚµ°°×ÖʺͺËËáµÄÐéÄâɸѡ
ÒѾÓÐ1È˻ظ´
ʹÓÃMolAICal¼ÆËãÒ©Îﻯѧ¹ýÂËÆ÷MCFs¼°MCE-18ÃèÊö·û
ÒѾÓÐ0È˻ظ´
ʹÓÃMolAICal·¢ÏÖµ°°×ÊÜÌåDZÔڵĻîÐÔ¿Ú´ü¼°Î»µã
ÒѾÓÐ0È˻ظ´
»ªÀíҩѧѧ˶Çóµ÷¼Á£¬×Ü·Ö324
ÒѾÓÐ0È˻ظ´
°ÄÃÅÀí¹¤´óѧÈ˹¤ÖÇÄÜÒ©Îï·¢ÏÖÖÐÐÄÕÐÊÕ2026¼¶²©Ê¿Ñо¿Éú£¨ÉêÇë-¿¼ºËÖÆ£©
ÒѾÓÐ10È˻ظ´

2Â¥2015-07-29 16:46:57
dylfgs
ľ³æ (ÖøÃûдÊÖ)
ÖÐÀɽ«
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 9823.7
- É¢½ð: 135
- ºì»¨: 6
- Ìû×Ó: 1263
- ÔÚÏß: 321.7Сʱ
- ³æºÅ: 1028007
- ×¢²á: 2010-05-25
- ÐÔ±ð: GG
- רҵ: Ò©Îï·ÖÎö

3Â¥2015-07-30 10:35:17














»Ø¸´´ËÂ¥